You are here: Home » International » News » Others
Lazard in talks with China, India, Japan on restructuring Sri Lanka's debt
Inter-governmental panel on the cards to resolve Chabahar Port row
Business Standard

Lupin gets nod for arthritis drug 'Rymti' from Canadian health authority

It underscores the scientific success of the company's biosimilar programmes and commitment to advancing healthcare through innovation, he added

Topics
Lupin | Arthritis | health news

Press Trust of India  |  New Delhi 



Lupin
Lupin

Drug maker on Tuesday said its biosimilar product Rymti, indicated for the treatment of arthritis, has received approval from the Canadian health authority.

The company's product is the biosimilar of reference drug Enbrel (Etanercept).

The product is indicated for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis , plaque psoriasis and paediatric plaque psoriasis.

"The approval for Rymti in Canada is a key milestone in our endeavours to improve access to medicines," Biotech President Cyrus Karkaria said in a statement.

It underscores the scientific success of the company's biosimilar programmes and commitment to advancing healthcare through innovation, he added.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)


Subscribe to Business Standard Premium

Exclusive Stories, Curated Newsletters, 26 years of Archives, E-paper, and more!

Insightful news, sharp views, newsletters, e-paper, and more! Unlock incisive commentary only on Business Standard.

Download the Business Standard App for latest Business News and Market News .

First Published: Tue, September 13 2022. 16:36 IST

RECOMMENDED FOR YOU

.